XML 30 R15.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment Data | 12 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
Segment Data | Segment DataThe Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Medical Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumer and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Pharmaceutical Systems. Life Sciences Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. With the emergency use authorization approval of the BD Veritor™ At-Home COVID-19 Test, Life Sciences also serves patients directly. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences. Interventional Interventional provides vascular, urology, oncology and surgical specialty products that are intended, with the exception of the V. Mueller TM surgical and laparoscopic instrumentation products, to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, individual healthcare professionals, extended care facilities, alternate site facilities and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment. Prior to its spin-off on April 1, 2022, the Company reported the Diabetes Care business as an organizational unit within the Medical segment. As such, historical financial information of the Medical segment has been recast in the tables below to reflect the total segment revenues and revenues from continuing operations. Revenues and operating income from the Diabetes Care business prior to its spin-off are included in Income from Discontinued Operations, Net of Tax. Assets and liabilities associated with the Diabetes Care business are classified as assets and liabilities of discontinued operations in the Company’s consolidated balance sheet as of September 30, 2021. See Note 2 for further information. Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars) | 2022 |  | 2021 |  | 2020
| United States |  | International |  | Total |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions (a) | $ | 2,483 |  |  | $ | 1,825 |  |  | $ | 4,308 |  |  | $ | 2,253 |  |  | $ | 1,848 |  |  | $ | 4,101 |  |  | $ | 1,979 |  |  | $ | 1,617 |  |  | $ | 3,596 |
Medication Management Solutions | 1,935 |  |  | 598 |  |  | 2,533 |  |  | 1,863 |  |  | 570 |  |  | 2,432 |  |  | 1,865 |  |  | 589 |  |  | 2,454 |
Pharmaceutical Systems (a) | 533 |  |  | 1,468 |  |  | 2,001 |  |  | 428 |  |  | 1,400 |  |  | 1,828 |  |  | 404 |  |  | 1,183 |  |  | 1,587 |
Total segment revenues | $ | 4,950 |  |  | $ | 3,891 |  |  | $ | 8,841 |  |  | $ | 4,544 |  |  | $ | 3,817 |  |  | $ | 8,361 |  |  | $ | 4,247 |  |  | $ | 3,389 |  |  | $ | 7,637 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 2,190 |  |  | $ | 1,995 |  |  | $ | 4,185 |  |  | $ | 2,477 |  |  | $ | 2,748 |  |  | $ | 5,225 |  |  | $ | 1,872 |  |  | $ | 1,659 |  |  | $ | 3,532 |
Biosciences | 542 |  |  | 838 |  |  | 1,379 |  |  | 503 |  |  | 802 |  |  | 1,305 |  |  | 465 |  |  | 678 |  |  | 1,143 |
Total segment revenues | $ | 2,732 |  |  | $ | 2,833 |  |  | $ | 5,564 |  |  | $ | 2,980 |  |  | $ | 3,550 |  |  | $ | 6,530 |  |  | $ | 2,337 |  |  | $ | 2,337 |  |  | $ | 4,675 |
Interventional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 1,094 |  |  | $ | 306 |  |  | $ | 1,400 |  |  | $ | 1,023 |  |  | $ | 274 |  |  | $ | 1,296 |  |  | $ | 891 |  |  | $ | 230 |  |  | $ | 1,121 |
Peripheral Intervention | 960 |  |  | 799 |  |  | 1,759 |  |  | 931 |  |  | 780 |  |  | 1,711 |  |  | 871 |  |  | 640 |  |  | 1,511 |
Urology and Critical Care | 986 |  |  | 319 |  |  | 1,305 |  |  | 894 |  |  | 338 |  |  | 1,232 |  |  | 815 |  |  | 315 |  |  | 1,130 |
Total segment revenues | $ | 3,040 |  |  | $ | 1,424 |  |  | $ | 4,464 |  |  | $ | 2,847 |  |  | $ | 1,392 |  |  | $ | 4,239 |  |  | $ | 2,577 |  |  | $ | 1,186 |  |  | $ | 3,762 |
Total Company revenues from continuing operations | $ | 10,722 |  |  | $ | 8,148 |  |  | $ | 18,870 |  |  | $ | 10,371 |  |  | $ | 8,760 |  |  | $ | 19,131 |  |  | $ | 9,161 |  |  | $ | 6,912 |  |  | $ | 16,074 |
(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta. The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization. Certain prior-period amounts have been recast to reflect the spin-off of the Diabetes Care business in fiscal year 2022, as noted above.
(Millions of dollars) | 2022 |  | 2021 |  | 2020
Income from Continuing Operations Before Income Taxes |  |  |  |  |
Medical (a) (b) | $ | 2,215 |  |  | $ | 1,985 |  |  | $ | 1,675 |
Life Sciences (c) | 1,710 |  |  | 2,391 |  |  | 1,405 |
Interventional | 1,081 |  |  | 933 |  |  | 724 |
Total Segment Operating Income | 5,006 |  |  | 5,311 |  |  | 3,806 |
Acquisition-related integration and restructuring expense | (173) |  |  | (179) |  |  | (299) |
Net interest expense | (382) |  |  | (460) |  |  | (521) |
Other unallocated items (d) | (2,668) |  |  | (2,981) |  |  | (2,573) |
Total Income from Continuing Operations Before Income Taxes | $ | 1,783 |  |  | $ | 1,692 |  |  | $ | 414 |
Capital Expenditures |  |  |  |  |
Medical | $ | 602 |  |  | $ | 740 |  |  | $ | 435 |
Life Sciences | 213 |  |  | 297 |  |  | 192 |
Interventional | 130 |  |  | 125 |  |  | 119 |
Corporate and All Other | 28 |  |  | 32 |  |  | 22 |
Total Capital Expenditures | $ | 973 |  |  | $ | 1,194 |  |  | $ | 769 |
Depreciation and Amortization |  |  |  |  |
Medical | $ | 1,144 |  |  | $ | 1,097 |  |  | $ | 1,064 |
Life Sciences | 283 |  |  | 352 |  |  | 286 |
Interventional | 789 |  |  | 769 |  |  | 750 |
Corporate and All Other | 13 |  |  | 12 |  |  | 14 |
Total Depreciation and Amortization | $ | 2,229 |  |  | $ | 2,230 |  |  | $ | 2,115 |
(a)The amounts in 2022, 2021 and 2020 include charges of $72 million $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD Alaris TM infusion pumps in the Medication Management Solutions unit. (b)The amount in 2022 includes a charge of $54 million to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. The amount in 2020 included $41 million of charges to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units. These charges were recorded to Cost of products sold. (c)The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units. (d)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts in 2022, 2021 and 2020 also include pre-tax charges of $21 million, $361 million and $378 million, recorded to Other operating expense (income), net respectively, related to certain product liability matters, which is further discussed in Note 6. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada. Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars) | 2022 |  | 2021 |  | 2020
Revenues |  |  |  |  |
United States | $ | 10,722 |  |  | $ | 10,371 |  |  | $ | 9,161 |
EMEA | 4,043 |  |  | 4,548 |  |  | 3,734 |
Greater Asia | 3,047 |  |  | 3,069 |  |  | 2,384 |
Other | 1,058 |  |  | 1,142 |  |  | 794 |
| $ | 18,870 |  |  | $ | 19,131 |  |  | $ | 16,074 |
Long-Lived Assets |  |  |  |  |
United States | $ | 36,617 |  |  | $ | 35,896 |  |  | $ | 36,317 |
EMEA | 5,126 |  |  | 5,778 |  |  | 5,660 |
Greater Asia | 1,528 |  |  | 1,607 |  |  | 1,466 |
Other | 1,079 |  |  | 860 |  |  | 753 |
Corporate | 442 |  |  | 465 |  |  | 411 |
| $ | 44,792 |  |  | $ | 44,606 |  |  | $ | 44,606 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration